From October 17-19, 2024, the 18th International Liver Cancer Association (ILCA) Annual Conference, a prestigious academic event in the global liver cancer field, took place in Toronto, Canada. Liver cancer experts from around the world convened to discuss hot topics and the latest advancements in the basics and clinical aspects of liver cancer. This conference featured the latest research findings from scholars in the global liver cancer field. This article specially compiled the significant clinical research in the field of liver cancer treatment presented at this ILCA conference for the exchange and learning of peers. Our special correspondent from "Oncology Frontier" attended the conference on-site for in-depth coverage, and more exciting content was expected to be shared!

Latest Clinical Research Progress and Hottest Clinical Research Directions

Five Oral Presentations

O-13

Analysis by treatment period and baseline liver function in EMERALD-1: a Phase 3, randomized, placebocontrolled study of durvalumab with/without bevacizumab with TACE in participants with embolization-eligible unresectable hepatocellular carcinoma

O-14

A novel glypican-3-targeted chimeric antibody-based gamma/delta TCR for treating liver cancer

O-15

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: a large real-life worldwide population

O-16

Pathological response following neoadjuvant immunotherapy predicts for relapse-free survival in hepatocellular carcinoma

Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3

Nine Award-Winning Poster Presentations

P-1

Depth of response (DpR) and duration of response (DoR) are associated with overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Exploratory analyses of IMbrave150

P-3

Using a combined index of methylated SEPT9 with existing tumor markers as a screening test for early-stage hepatocellular carcinoma

P-9

Association Between Safety Net Hospitals and Treatment Delays in Hepatocellular Carcinoma

P-11

Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial

P-12

Unveiling the role of unfolded protein response in hepatocellular carcinoma behavior in TP53 and CTNNB1 genetic backgrounds

P-14

Modeling Hepatocellular Carcinoma by CRISPR Editing of Porcine Primary Hepatocytes

P-15

Extensive molecular profiling in Predicting Survival in patients with cholangiocarcinoma treated with Cisplatin/gemcitabine plus durvalumab, a large real-life worldwide population

P-16

COMBINED ANTI-PD1 THERAPY RELIEVES MDSC-MEDIATED IMMUNOSUPPRESSION AND REDUCES HEPATOCELLULAR CARCINOMA REGROWTH AFTER IRREVERSIBLE ELECTROPORATION

P-17

EXPLORATION OF HEPATOCELLULAR CARCINOMA NEOANTIGEN MR